Showing results (361-370 of 452) with videos related to

Sort By:
Pageof 46
Current Radiopharmaceuticals|November 10, 2017
18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and ImmunohistochemistryPaola Mapelli, Valentino Bettinardi, Federico Fallanca, et al.
Current Radiopharmaceuticals|November 22, 2019
Sentinel Node Identification in Melanoma: Current Clinical Impact, New Emerging SPECT Radiotracers and Technological Advancements. An Update of the Last DecadeNatale Quartuccio, Massimiliano Siracusa, Marco Pappalardo, et al.
Current Radiopharmaceuticals|December 13, 2017
PET Radiopharmaceuticals in Brazil and Belarus: Economic Comparison Using the Case of 18FDGSviatoslav Brinkevich, Leonardo Paredes Pires, Filipe Leal Portilho, et al.
Current Radiopharmaceuticals|February 8, 2019
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine TumoursVincenzo Cuccurullo, Giuseppe Danilo Di Stasio, Luigi Mansi
Current Radiopharmaceuticals|December 31, 2019
18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the ArtAngelo Castello, Sabrina Rossi, Egesta Lopci
Current Radiopharmaceuticals|March 5, 2019
Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?Vittorio Briganti, Vincenzo Cuccurullo, Giuseppe Danilo Di Stasio, et al.
Current Radiopharmaceuticals|October 20, 2018
Synthesis of [18F]FAZA Using Nosyl and Iodo Precursors for Nucleophilic RadiofluorinationWilliam Sun, Cheryl Falzon, Ebrahim Naimi, et al.
Current Radiopharmaceuticals|May 29, 2015
Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric PopulationLaura Evangelista, Francesco Bertagna, Mattia Bertoli, et al.
Current Radiopharmaceuticals|May 1, 2015
FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI SubjectsAndrea Ciarmiello, Maria Chiara Gaeta, Francesco Benso, et al.
Current Radiopharmaceuticals|May 12, 2020
In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive CellsVilde Y Stenberg, Asta Juzeniene, Øyvind S Bruland, et al.
Pageof 46